For release at 8:30 a.m.
Chad Rubin, Investor Relations Contact, The Trout Group LLC – 646-378-2947
DUSA Pharmaceuticals to Present at the
Canaccord Genuity 6th Annual
Cardiovascular, Aesthetics & Metabolic Disorders Conference
WILMINGTON, MASS. – November 29, 2011 — DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Canaccord Genuity 6th Annual Cardiovascular, Aesthetics & Metabolic Disorders Conference. The conference is being held at the St. Regis Hotel in San Francisco, California on December 6, 2011. Mr. Doman is scheduled to present at 2:20 p.m. Pacific Time (5:20 p.m. Eastern Time). Interested parties can access the live audio webcast of the presentation at www.dusapharma.com. An archived version of the presentation will be available on the DUSA website for 90 days following the presentation.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® PDT technology platform, and other dermatology products. Levulan® Kerastick® for topical solution plus DUSA’s BLU-U® blue light photodynamic therapy illuminator is currently approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp. DUSA also markets other dermatology products, including ClindaReach®. DUSA is based in Wilmington, Mass. Please visit our website at www.dusapharma.com.